News
Jupiter Neurosciences
JUNS · NASDAQ
$2.80+$0.05 (+1.82%)TodayMarket closed ·
Prev close $2.75
Latest news
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- Press releaseGlobe Newswire
Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value
- NewsAvi Kapoor
Dow Falls Over 300 Points; SAIC Shares Jump After Upbeat Q2 Results
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- Press releaseGlobe Newswire
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
- NewsAvi Kapoor
Dow Jumps 350 Points; BJ's Wholesale Club Posts Upbeat Earnings
- NewsHenry Khederian
Jupiter Neurosciences Stock Surges Friday: What's Driving the Action?
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
Jupiter Neurosciences Enters Definitive License Agreement With PharmAla For Its Patented, Non-Racemic MDMA Formulation ALA-002
- Press releaseGlobe Newswire
PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
Jupiter Neurosciences, Inc. Announces Reverse Stock Split
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
Jupiter Neurosciences Enters License Agreement With PharmAla Biotech For Perpetual Exclusive U.S. Rights To ALA-002; Deal Worth Up To $100M With Milestone Payments
- Press releaseGlobe Newswire
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
- Press releaseGlobe Newswire
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
- Press releaseGlobe Newswire
Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson
- News
Jupiter Neurosciences Initiates Patient Enrollment In Its Phase 2a RESET Clinical Study For JOTROL In Parkinson's Disease
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- NewsDylan Berman
Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releaseBusiness Wire
Jupiter Neurosciences Investor News: Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation – JUNS
- Press releaseBusiness Wire
Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation – JUNS
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
US Stocks Mixed; GE Aerospace Posts Upbeat Earnings
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.